“Minerva achieved a significant milestone in 2023, with the acceptance of our NDA for roluperidone, which if approved will be the first ever medication for negative symptoms of schizophrenia to receive regulatory approval. This milestone also brings hope to the patients, families and physicians caring for those experiencing negative symptoms of schizophrenia who currently have no treatment options,” said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NERV:
